secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0001558370-23-007393
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics reports Q1 BRIUMVI net sales of $7.8M in first partial launch quarter
--------------------------------------------------------------------------------

- BRIUMVI net sales $7.8M for Q1 2023; over 400 prescriptions from 165+ HCPs at 125+ centers.
- Payor coverage in place for over 50% of covered lives; permanent J-code effective July 1, 2023.
- Net loss narrowed to $39.2M vs $69.0M YoY; cash $139.7M with $20M credit facility, funding into mid-2024.
- CHMP positive opinion for EU approval of BRIUMVI for RMS; additional data presented at ACTRIMS/AAN.
- R&D expense $15.9M (down from $48M) driven by lower manufacturing/clinical costs post-approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000155837023007393/0001558370-23-007393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000155837023007393/tgtx-20230501x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-007393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer